Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Significance: Synthetic nanoparticles containing either protein or peptide antigen and the immunosuppressant rapamycin are capable of inducing durable and specific resistance to mounting immune responses toward the antigen. This immunological tolerance operates on lymphocytes even after multiple immunogenic challenges with the antigen and adding enhancers of immune responses (adjuvants). As a result, the animals treated with these tolerogenic nanoparticles (tNPs) show reduced allergic hypersensitivity disorders, protection from disease relapse in a model of multiple sclerosis, and prevention of inhibitory antidrug antibody responses in an animal model of hemophilia A. These results show the potential for nanocarriers to modify the immunoreactivity of a given molecule by providing tolerogenic instructions to the immune system, thereby preventing or reversing pathological and neutralizing immune responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Further, tolerogenic rapamycin nanoparticles, but not rapamycin in free form, have been shown to be able to inhibit both cellular and humoral immune response and induce Tregs in mice (40).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [40]
Citations
Cites
Steinman, R. M., Hawiger, D., & Nussenzweig, M. C. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141040 · Cited by 3,122
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
Bachmann, M. F., & Jennings, G. T. (2010) · Nature Reviews Immunology · doi:10.1038/nri2868 · Cited by 2,106 · cited 7×
“Thomson and colleagues (26, 27) demonstrated that treating DCs with rapamycin, an inhibitor of the mTOR pathway, induces a tolerogenic DC phenotype capable of inducing Treg differentiation and antigen-specific immune tolerance that is resistant to the proinflammatory cascade triggered by TLR signaling.”
InfluentialmTOR regulates memory CD8 T-cell differentiation
Araki, K., Turner, A. P., Shaffer, V. O., Gangappa, S., Keller, S. A., Bachmann, M. F., Larsen, C. P., & Ahmed, R. (2009) · Nature · doi:10.1038/nature08155 · Cited by 1,575 · cited 1×
“In fact, free rapamycin, administered at an equivalent dose as that used in tNP treatment, showed the opposite trend with respect to inhibition of OVA-specific T-cell expansion and induction of antigen-specific Tregs, perhaps due to the direct effect of free rapamycin on enhancing effector memory T-cell formation (40).”
Goodnow, C. C., Crosbie, J., Adelstein, S., Lavoie, T. B., Smith-Gill, S. J., Brink, R. A., Pritchard-Briscoe, H., Wotherspoon, J. S., Loblay, R. H., Raphael, K., et al. (1988) · Nature · doi:10.1038/334676a0 · Cited by 1,565 · cited 1×
“The transgenic BCR is specific for hen egg lysozyme (HEL), and the presence of this protein results in cell activation of MD4 B cells in vivo and in vitro (33).”
Regulation of Immune Responses by mTOR
Powell, J. D., Pollizzi, K. N., Heikamp, E. B., & Horton, M. R. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075024 · Cited by 836 · cited 2×
“However, conventional therapy with free rapamycin requires chronic systemic administration, resulting in broad immunosuppression due to its direct effect on lymphocytes (28), whereas low doses of rapamycin may paradoxically augment effector T-cell memory (29).”
Synthesis and characterization of PLGA nanoparticles
Astete, C. E., & Sabliov, C. M. (2006) · Journal of Biomaterials Science, Polymer Edition · doi:10.1163/156856206775997322 · Cited by 776 · cited 1×
“tNPs containing both antigen and rapamycin were prepared using a water-in-oil-in-water double emulsion solvent evaporation method (44, 45).”
Engineering synthetic vaccines using cues from natural immunity
Irvine, D. J., Swartz, M. A., & Szeto, G. L. (2013) · Nature Materials · doi:10.1038/nmat3775 · Cited by 594 · cited 8×
“Thomson and colleagues (26, 27) demonstrated that treating DCs with rapamycin, an inhibitor of the mTOR pathway, induces a tolerogenic DC phenotype capable of inducing Treg differentiation and antigen-specific immune tolerance that is resistant to the proinflammatory cascade triggered by TLR signaling.”
InfluentialTargeted disruption of the mouse factor VIII gene produces a model of haemophilia A
Bi, L., Lawler, A. M., Antonarakis, S. E., High, K. A., Gearhart, J. D., & Kazazian, H. H. (1995) · Nature Genetics · doi:10.1038/ng0595-119 · Cited by 593 · cited 1×
“tNPs containing both antigen and rapamycin were prepared using a water-in-oil-in-water double emulsion solvent evaporation method (44, 45).”
How Tolerogenic Dendritic Cells Induce Regulatory T Cells
Maldonado, R. A., & von Andrian, U. H. (2010) · Advances in Immunology · doi:10.1016/b978-0-12-380995-7.00004-5 · Cited by 541 · cited 1×
“The codelivery of antigen and rapamycin provide an instruction set that could allow for the conditioning of tolerogenic DCs capable of inducing CD4+ Treg (22, 23).”
Self-citationUpdated assessment of the prevalence, spectrum and case definition of autoimmune disease
Hayter, S. M., & Cook, M. C. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.02.001 · Cited by 464 · cited 1×
“Clin Rev Allergy Immunol 37(2):114–124.”
Cited by
Items 201–300 of 452
Advancing drug delivery systems for the treatment of multiple sclerosis
Tabansky, I., Messina, M. D., Bangeranye, C., Goldstein, J., Blitz-Shabbir, K. M., Machado, S., Jeganathan, V., Wright, P., Najjar, S., Cao, Y., et al. (2015) · Immunologic Research · doi:10.1007/s12026-015-8719-0 · Cited by 37
“Similarly, Selecta Bioscience is developing nanoparticle platforms to induce tolerogenic T and B cell responses in murine models of MS and hemophilia [89].”
BackgroundShah, S., Daneshmandi, S., Hughes, K. R., Yu, S., Bedoya, A. M., Shea, L. D., & Luo, X. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.04.030 · Cited by 32
“The significant protection afforded by donor antigen-coupled PLG NPs in this transplant model advances the notion that highly anionic PLG NPs with approximately 500 nm diameter in size indeed provide a robust platform for immune engineering for transplantation tolerance as previously demonstrated for autoimmunity and…”
BackgroundCell and Tissue Instructive Materials for Central Nervous System Repair
Rocha, L. A., Silva, D., Barata‐Antunes, S., Cavaleiro, H., Gomes, E. D., Silva, N. A., & Salgado, A. J. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201909083 · Cited by 34
Biomaterials-based formulations and surfaces to combat viral infectious diseases
Kumari, S., & Chatterjee, K. (2021) · APL Bioengineering · doi:10.1063/5.0029486 · Cited by 31
Shahzad, K. A., Wan, X., Zhang, L., Pei, W., Zhang, A., Younis, M., Wang, W., & Shen, C. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1447049 · Cited by 31
“…facilitates the researches using biomimetic NPs as modulators in autoimmunity and allograft rejection by coating or encapsulating antigens, toxins and/or cytokines (Tsai et al., 2010; Getts et al., 2012; Bryant et al., 2014; Fisher et al., 2015; Hotaling et al., 2015; Maldonado et al., 2015).”
BackgroundSelf-citationEnhancement of the Tolerogenic Phenotype in the Liver by ImmTOR Nanoparticles
Ilyinskii, P. O., Roy, C. J., LePrevost, J., Rizzo, G. L., & Kishimoto, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.637469 · Cited by 30
“The principal target organs of biodistribution for intravenously delivered ImmTOR are spleen and liver (7).”
BackgroundMethodSelf-citationRecent advancements in nanoparticle-mediated approaches for restoration of multiple sclerosis
Rahiman, N., Mohammadi, M., Alavizadeh, S. H., Arabi, L., Badiee, A., & Jaafari, M. R. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.009 · Cited by 30
Counteracting Immunosenescence—Which Therapeutic Strategies Are Promising?
Hieber, C., Grabbe, S., & Bros, M. (2023) · Biomolecules · doi:10.3390/biom13071085 · Cited by 30
Sutter, D., Dzhonova, D. V., Prost, J., Bovet, C., Banz, Y., Rahnfeld, L., Leroux, J., Rieben, R., Vögelin, E., Plock, J. A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-45759-y · Cited by 30
Lim, H. H., Yi, H., Kishimoto, T., Gao, F., Sun, B., & Kishnani, P. S. (2017) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2017.03.005 · Cited by 30
Self-citationImmunomodulatory nano-preparations for rheumatoid arthritis
Li, C., Han, Y., Luo, X., Qian, C., Li, Y., Su, H., & Du, G. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2152136 · Cited by 30
Liu, C., Zhu, J., Mi, Y., & Jin, T. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02663-z · Cited by 29
Potential for Antigen-Specific Tolerizing Immunotherapy in Systematic Lupus Erythematosus
Robinson, S., & Thomas, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.654701 · Cited by 31
The deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapy
Puzzo, F., & Kay, M. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.041 · Cited by 31
“106 Preclinical studies have demonstrated that ImmTOR enables AAV vector administration in animal models that developed high titers of NAbs.”
Manipulation of Regulatory Dendritic Cells for Induction Transplantation Tolerance
Que, W., Guo, W.-Z., & Li, X. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.582658 · Cited by 29
“induced antigenspecific immunological tolerance using polymeric synthetic nanoparticles loaded with antigens and rapamycin, which resulted in suppression of T cell activation and an increase in regulatory cells (138).”
BackgroundZhang, X., Liu, D., He, M.-H., Lin, M., Tu, C., & Zhang, B. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1872342 · Cited by 28
“HEL46-61 was prepared using double emulsion method as described previously.(18,19) Briefly, PLGA, pegylated polylactic acid (PLA-PEG), with or without rapamycin was dissolved”
MethodSrivastava, A., Arlian, B. M., Pang, L., Kishimoto, T., & Paulson, J. C. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00212 · Cited by 29
Self-citationNot Just for Tumor Targeting: Unmet Medical Needs and Opportunities for Nanomedicine
Lepeltier, É., Nuhn, L., Lehr, C., & Zentel, R. (2015) · Nanomedicine · doi:10.2217/nnm.15.132 · Cited by 28
Yang, Y., & Santamaría, P. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113898 · Cited by 30
“Whereas administration of NPs delivering rapamycin alone delayed the onset of EAE only slightly, administration of NPs delivering only the PLP 139-151 peptide could not prevent disease development, but suppressed disease relapse [92].”
InfluentialAddressing the key issue: Antigen-specific targeting of B cells in autoimmune diseases
Holborough-Kerkvliet, M. D., Kroos, S., van de Wetering, R., & Toes, R. E. M. (2023) · Immunology Letters · doi:10.1016/j.imlet.2023.05.005 · Cited by 29
Innovative drug delivery strategies to the CNS for the treatment of multiple sclerosis
Mwema, A., Muccioli, G. G., & Rieux, A. D. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.10.052 · Cited by 28
Tolerogenic Nanoparticles to Treat Islet Autoimmunity
Neef, T., & Miller, S. D. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0914-z · Cited by 28
Advances in understanding disease mechanisms and potential treatments for Crigler–Najjar syndrome
Bortolussi, G., & Muro, A. F. (2018) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1495558 · Cited by 31
Nanoparticle-based immunotherapy: state of the art and future perspectives
Gioacchino, M. D., Petrarca, C., Gatta, A., Scarano, G., Farinelli, A., Valle, L. D., Lumaca, A., Biondo, P. D., Paganelli, R., & Giampaolo, L. D. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1762572 · Cited by 28
Cell and biomaterial delivery strategies to induce immune tolerance
Scotland, B. L., Shaw, J. R., Dharmaraj, S., Caprio, N., Cottingham, A. L., Lasola, J. J., Sung, J. J., & Pearson, R. M. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115141 · Cited by 27
Chen, N., Peine, K. J., Collier, M. A., Gautam, S., Jablonski, K., Guerau‐de‐Arellano, M., Ainslie, K. M., & Bachelder, E. M. (2017) · Advanced Biosystems · doi:10.1002/adbi.201700022 · Cited by 26
Bioengineering strategies for inducing tolerance in autoimmune diabetes
Bækkeskov, S., Hubbell, J. A., & Phelps, E. A. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.007 · Cited by 27
Sabbata, G. D., Boisgérault, F., Guarnaccia, C., Iaconcig, A., Bortolussi, G., Collaud, F., Ronzitti, G., Sola, M. S., Vidal, P., Rouillon, J., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.11.005 · Cited by 26
Self-citationAjit, J., Cassaidy, B., Tang, S. N., Solanki, A., Chen, Q., Shen, J., & Esser-Kahn, A. P. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202200819 · Cited by 25
Verhagen, J., Wegner, A., & Wraith, D. C. (2015) · Immunology · doi:10.1111/imm.12458 · Cited by 25
Enhancing the Response Rate to Recombinant Uricases in Patients with Gout
Schlesinger, N., Padnick‐Silver, L., & LaMoreaux, B. D. (2022) · BioDrugs · doi:10.1007/s40259-022-00517-x · Cited by 25
“Further, this tolerogenic dendritic cell control inhibits B cells and T cells from producing antidrug antibodies against pegadricase via prevention of interleukin-2 production [39, 56].”
BackgroundTherapeutic potential of tolerance-based peptide vaccines in autoimmune diseases
Yu, X., Mai, Y., Wei, Y., Yu, N., Gao, T., & Yang, J. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109740 · Cited by 24
Tolerance-inducing therapies in coeliac disease — mechanisms, progress and future directions
Sollid, L. M. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00895-3 · Cited by 24
“Such nanoparticles have been shown to inhibit CD4 + and CD8 + T cell activation, to increase numbers of T reg cells and to give durable B cell tolerance resistant to multiple immunogenic challenges in mice 125 .”
Mashayekhi, K., Khazaie, K., Faubion, W. A., & Kim, G. B. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.03.030 · Cited by 26
“These outcomes led to a reduction in relapses in EAE, the suppression of hypersensitivity reactions, and the production of anti-coagulation factor-VIII antibodies in hemophilia A mice [103].”
BackgroundAdvances in engineered nanosystems: immunomodulatory interactions for therapeutic applications
Khatua, R., Bhar, B., Dey, S., Jaiswal, C., Victoria, J. I., & Mandal, B. B. (2024) · Nanoscale · doi:10.1039/d4nr00680a · Cited by 25
Cellular and molecular targeting for nanotherapeutics in transplantation tolerance
Hlavaty, K. A., Luo, X., Shea, L. D., & Miller, S. D. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.03.013 · Cited by 25
“described the induction of tolerance using biodegradable nanoparticles carrying either protein or peptide Ags and rapamycin [95].”
BackgroundTherapeutic Targeting of Autoreactive B Cells: Why, How, and When?
Stensland, Z. C., Cambier, J. C., & Smith, M. J. (2021) · Biomedicines · doi:10.3390/biomedicines9010083 · Cited by 23
“Similar results were found by another group who used tNPs containing FVIII and rapamycin, an inhibitor of the mTOR pathway and potent immune modulator [12].”
ResultWeber, N. D., Odriozola, L., Ros‐Gañán, I., García-Porrero, G., Salas, D., Argemí, J., Combal, J. P., Kishimoto, T., & González‐Aseguinolaza, G. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100713 · Cited by 27
Self-citationTolerogenic Nano-/Microparticle Vaccines for Immunotherapy
Liu, Q., Chen, G., Liu, X., Tao, L., Fan, Y., & Xia, T. (2024) · ACS Nano · doi:10.1021/acsnano.3c11647 · Cited by 31
Tostanoski, L. H., Eppler, H. B., Xia, B., Zeng, X., & Jewell, C. M. (2019) · Biomaterials Science · doi:10.1039/c8bm01572d · Cited by 25
Liver Cell Type-Specific Targeting by Nanoformulations for Therapeutic Applications
Kaps, L., Limeres, M. J., Schneider, P. M., Svensson, M., Zeyn, Y., Ghazi, S. F.-E., Cacicedo, M. L., Galle, P. R., Gehring, S., & Bros, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411869 · Cited by 25
“In a follow-up study [32], the aforementioned LSEC-targeting tolerization approach using OVA as a model allergen showed similar efficacy as using PLGA-based NPs containing the mTOR inhibitory drug, rapamycin (immTOR), previously reported to passively target and tolerize DCs, thereby inducing Treg and attenuating B cel…”
BackgroundMethodMultifunctional nanomedicine strategies to manage brain diseases
Faria, P. D. P., Pacheco, C., Moura, R. P., Sarmento, B. F. C. C., & Martins, C. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01256-w · Cited by 22
“tested tolerogenic NPs co-loaded with rapamycin and PLP139–151 in different animal disease models, including a model of relapsing–remitting EAE (R-EAE) [164].”
BackgroundPereira, M. A., Rebouças, J. D. S., Carvalho, R. D. S. F., de Redín, I. L., Guerra, P. V., Gamazo, C., Brodskyn, C., Irache, J. M., & Santos-Magalhães, N. S. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.02.011 · Cited by 22
Nanomedicine Approaches Against Parasitic Worm Infections
Li, P., Coronado, P. E. R., Longstaff, X. R., Tarashansky, A. J., & Wang, B. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701494 · Cited by 23
Biomaterials for Modulating Lymphatic Function in Immunoengineering
Sestito, L. F., & Thomas, S. N. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00047 · Cited by 22
Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies
Scott, D. W., & Pratt, K. P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03078 · Cited by 23
“The use of rapamycin-containing nanoparticles for tolerance was successfully used by our group for FVIII (91), and by others for modulating autoimmunity (89) or the immune response to therapeutic immunotoxins, which are highly immunogenic (92, 93).”
BackgroundSelf-citationLymph-directed nitric oxide increases immune cell access to lymph-borne nanoscale solutes
Sestito, L. F., & Thomas, S. N. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120411 · Cited by 23
Wen, J., Moloney, E. B., Canning, A., Donohoe, E., Ritter, T., Wang, J., Xiang, D., Wu, J., & Li, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105833 · Cited by 22
Cellular biodistribution of polymeric nanoparticles in the immune system
Yang, Y., & Luo, W.-H. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.02.011 · Cited by 22
Oh, C., Jung, H. S., Park, J., Awad, J., Jiang, D., Dowling, D. J., & Im, H. (2025) · ACS Nano · doi:10.1021/acsnano.5c04836 · Cited by 23
Peptide‐Based Vaccination Therapy for Rheumatic Diseases
Wang, B., Chen, S., Zheng, Q., Liu, Y., & Shi, G. (2020) · Journal of Immunology Research · doi:10.1155/2020/8060375 · Cited by 22
Neuroprotective Potential of Dendritic Cells and Sirtuins in Multiple Sclerosis
Piacente, F., Bottero, M., Benzi, A., Vigo, T., Uccelli, A., Bruzzone, S., & Ferrara, G. B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084352 · Cited by 22
Zhao, J., He, P., Jiang, M., He, C., Zhao, Y., Zhang, Z., Zhang, Z., Du, G., & Sun, X. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.018 · Cited by 21
Antigen-based immunotherapy (AIT) for autoimmune and allergic disease
MacLeod, M. K. L., & Anderton, S. M. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.05.003 · Cited by 22
“Such approaches have been successfully used in animal models of allergy and autoimmunity [31 (cid:2) ,32 (cid:2) ].”
MethodLatha, T. S., Lomada, D., Dharani, P. K., Muthukonda, S. V., & Reddy, M. C. (2016) · RSC Advances · doi:10.1039/c5ra18974h · Cited by 21
Xu, X., Bian, L., Shen, M., Li, X., Zhu, J., Chen, S., Xiao, L., Zhang, Q., Chen, H., Xu, K., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4419-8 · Cited by 21
Leveraging Immunopeptidomics To Study and Combat Infectious Disease
Leddy, O. K., White, F. M., & Bryson, B. D. (2021) · mSystems · doi:10.1128/msystems.00310-21 · Cited by 23
“Cross-reactive epitopes identified in immunopeptidomic studies could in principle be targeted by therapies designed to induce epitope-specific immune tolerance (61, 62) and mitigate autoimmunity associated with infection.”
BackgroundDesign and Evaluation of Synthetic Delivery Formulations for Peptide-Based Cancer Vaccines
Song, K., & Pun, S. H. (2024) · BME Frontiers · doi:10.34133/bmef.0038 · Cited by 20
“Delivering antigens with tolerogenic immunomodulators can even induce antigen-specific immune tolerance and inhibition of T cell activation [93].”
BackgroundMaulloo, C. D., Cao, S., Watkins, E. A., Raczy, M. M., Solanki, A., Nguyen, M., Reda, J. W., Shim, H.-N., Wilson, D. S., Swartz, M. A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.714842 · Cited by 20
“Successful strategies have included coating PLGA microparticles with DEC-205 DC-targeting antibodies or P-D2 integrin-targeting peptides (8) or encapsulating PLGA nanoparticles with antigen (such as MOG peptide) and immunosuppressive agents such as IL-10 (9) or rapamycin (10) to promote tolerogenicDCmaturation.”
MethodImmunomodulatory and immunoregulatory nanomedicines for autoimmunity
Montaño, J. A. B., Garnica, J., & Santamaría, P. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101535 · Cited by 21
“In contrast, delivery of NPs loaded with either rapamycin or peptide alone could not suppress the onset of EAE, although the latter could suppress disease relapse [64].”
Tip-concentrated microneedle patch delivering everolimus for therapy of multiple sclerosis
Yang, Y., Wei, S., Wang, N., Ren, Y., & Liu, H. (2022) · Biomaterials Advances · doi:10.1016/j.bioadv.2022.212729 · Cited by 197
Raposo, C. J., Cserny, J. D., Serena, G., Chow, J., Cho, P., Liu, H., Kotler, D., Sharei, A., Bernstein, H., & John, S. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.869669 · Cited by 22
Zala, A., & Thomas, R. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac115 · Cited by 22
Ilyinskii, P. O., Roy, C. J., Michaud, A. M., Rizzo, G. L., Capela, T., Leung, S. S., & Kishimoto, T. (2023) · PNAS Nexus · doi:10.1093/pnasnexus/pgad394 · Cited by 22
“ImmTOR nanoparticles were prepared as previously described (25, 26).”
MethodInfluentialSelf-citationThe Application of Nanovaccines in Autoimmune Diseases
Tang, Y., & Li, L. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s440612 · Cited by 22
“24 This may be because PLGA nanoparticles can encapsulate drugs or antigens in nanoparticles, which can not only protect drugs or antigens from enzymatic hydrolysis but also enable long-term slow release of drugs or antigens to achieve the purpose of long-term drug action or durable immune…”
BackgroundBioconjugate Strategies for the Induction of Antigen-Specific Tolerance in Autoimmune Diseases
Yu, C., Xi, J., Li, M., An, M., & Liu, H. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00632 · Cited by 21
Sadtler, K., Collins, J., Byrne, J. D., & Langer, R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.021 · Cited by 20
“e immune system makes it a target of drug delivery through nanoparticles [89,135,136],”
BackgroundSelf-citationExploiting Rational Assembly to Map Distinct Roles of Regulatory Cues during Autoimmune Therapy
Oakes, R. S., Tostanoski, L. H., Kapnick, S. M., Froimchuk, E., Black, S. K., Zeng, X., & Jewell, C. M. (2021) · ACS Nano · doi:10.1021/acsnano.0c07440 · Cited by 20
Designing antigens for the prevention and treatment of autoimmune diseases
Wraith, D. C. (2017) · Current Opinion in Chemical Engineering · doi:10.1016/j.coche.2017.12.004 · Cited by 21
Aliphatic Polyester‐Based Materials for Enhanced Cancer Immunotherapy
Chin, A. L., Wang, X., & Tong, R. (2021) · Macromolecular Bioscience · doi:10.1002/mabi.202100087 · Cited by 19
Wan, X., Pei, W., Shahzad, K. A., Zhang, L., Song, S., Jin, X., Wang, L., Zhao, C., & Shen, C. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800108 · Cited by 19
“Numerous researchers around the world have reported the biomimetic micro- and nanoparticles (MNPs) carrying myelin peptides or proteins along with toxin or regulatory molecules for the treatment of EAE or MS (30, 40, 41).”
BackgroundProactively Reducing Anti‐Drug Antibodies via Immunomodulatory Bioconjugation
Zhang, P., Jain, P., Tsao, C., Wu, K., & Jiang, S. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201814275 · Cited by 18
Wang, S.-H., Serr, I., Digigow, R. G., Metzler, B., Surnov, A., Gottwick, C., Alsamman, M., Krzikalla, D., Heine, M., Zahlten, M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1542380 · Cited by 21
Tissue‐Targeted Drug Delivery Strategies to Promote Antigen‐Specific Immune Tolerance
Rui, Y., Eppler, H. B., Yanes, A. A., & Jewell, C. M. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202202238 · Cited by 22
Harnessing the lymph node microenvironment
O’Neill, N. A., Eppler, H. B., Jewell, C. M., & Bromberg, J. S. (2017) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000488 · Cited by 19
Using gold nanoparticles for enhanced intradermal delivery of poorly soluble auto-antigenic peptides
Singh, R., Malosse, C., Davies, J. E., MALISSEN, B., Kochba, E., Levin, Y., Birchall, J. C., Coulman, S. A., Mous, J., McAteer, M. A., et al. (2020) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2020.102321 · Cited by 18
Biomimetic Nanosponges for Treating Antibody-Mediated Autoimmune Diseases
Jiang, Y., Fang, R. H., & Zhang, L. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00814 · Cited by 19
Adytia, G. J., Sutanto, H., Pratiwi, L., & Fetarayani, D. (2025) · Immuno · doi:10.3390/immuno5010006 · Cited by 19
Tolerance induction in hemophilia: innovation and accomplishments
Sherman, A., Biswas, M., & Herzog, R. W. (2018) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000446 · Cited by 18
AAV Vectored Immunoprophylaxis for Filovirus Infections
Rghei, A. D., van Lieshout, L. P., Santry, L. A., Guilleman, M. M., Thomas, S. P., Susta, L., Karimi, K., Bridle, B. W., & Wootton, S. K. (2020) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed5040169 · Cited by 17
Chen, H., Song, J., Zeng, L., Zha, J., Zha, J., Chen, A., Liu, Y., Dong, Z., & Chen, G. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116505 · Cited by 16
A comprehensive overview of tolerogenic vaccine adjuvants and their modes of action
Arve-Butler, S., & Moorman, C. D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1494499 · Cited by 21
“In combination with other adjuvants, tolerogenic vaccines using both TGF-b and IL-10 suppressed disease in CIA (86) and reduced anti-drug antibodies toward FVIII (87).”
InfluentialGosselin, E. A., Tostanoski, L. H., & Jewell, C. M. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0089-1 · Cited by 18
Inhibitor Formation in Congenital Hemophilia A: an Immunological Perspective
Delignat, S., Rayes, J., Russick, J., Kaveri, S. V., Lacroix‐Desmazes, S., & The ABIRISK consortium (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1657777 · Cited by 16
A Chromatin-Mimetic Nanomedicine for Therapeutic Tolerance Induction
Li, B., Yuan, Z., McMullen, P., Xie, J., Jain, P. R., Hung, H., Xu, S., Zhang, P., Lin, X., Wu, K., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b04314 · Cited by 16
Dangkoub, F., Sankian, M., Tafaghodi, M., Jaafari, M. R., & Badiee, A. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.09.037 · Cited by 18
Nano-Immunomodulation: A New Strategy for Skeletal Muscle Diseases and Aging?
Millozzi, F., Papait, A., Bouché, M., Parolini, O., & Palacios, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021175 · Cited by 16
Jamal, M. E., & Shibli, F. (2024) · Exploration of Immunology · doi:10.37349/ei.2024.00136 · Cited by 16
Mennini, M., Piccirillo, M., Furio, S., Valitutti, F., Ferretti, A., Strisciuglio, C., Filippo, M. D., Parisi, P., Peroni, D. G., Nardo, G. D., et al. (2024) · Frontiers in Allergy · doi:10.3389/falgy.2024.1473352 · Cited by 17
Ilić, N., Kosanović, M., Gruden‐Movsesijan, A., Glamočlija, S., Sofronić‐Milosavljević, L., Čolić, M. J., & Tomić, S. (2021) · Immunology Letters · doi:10.1016/j.imlet.2021.04.012 · Cited by 15
Carey, S. T., Gammon, J. M., & Jewell, C. M. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01075-5 · Cited by 16
Potential Pharmacologic Targets for the Prevention of Rheumatoid Arthritis
Isaacs, J. D., & Iqbal, K. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.04.020 · Cited by 15
Nanosystems and exosomes as future approaches in treating multiple sclerosis
Sidoryk‐Wȩgrzynowicz, M., Dąbrowska‐Bouta, B., Sułkowski, G., & Strużyńska, L. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15478 · Cited by 15
“…of innate immunity Cappellano et al. (2014) PLGA NPs PLP139-151 + rapamycin Induction of immune tolerance; inhibition of CD4+ and CD8+ T cells Maldonado et al. (2015) Liposomes PEG Decreased level of circulating monocytes/macrophages Tran et al. (1998) PLGA NPs Getts et al. (2014) AuNPs…”
BackgroundNguyen, T. L., Phan, N. M., & Kim, J. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c05428 · Cited by 15
Navigating the nano-bio immune interface: advancements and challenges in CNS nanotherapeutics
Moulton, C., Baroni, A., Quagliarini, E., Leone, L., Digiacomo, L., Morotti, M., Caracciolo, G., Podda, M. V., & Tasciotti, E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1447567 · Cited by 15
Nanotechnology Approaches for Mitigating Biologic Immunogenicity: A Literature Review
Alanazi, J. S., Aleanizy, F. S., & Alqahtani, F. Y. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17070888 · Cited by 14
Wang, W., Fang, K., Li, M.-C., Chang, D., Shahzad, K. A., Xu, T., Zhang, L., Gu, N., & Shen, C. (2016) · Oncotarget · doi:10.18632/oncotarget.7519 · Cited by 14
“Moreover, PLGA-NPs containing either protein or peptide and rapamycin [35] as well as gold-NPs with a PEG surface monolayer [36] as vehicles for the delivery of auto antigens to DCs are able to promote the induction of CD4+ CD25+ Foxp3+ regulatory T cells and antigen-specific immunological tolerance.”
BackgroundLi, J., Qiu, D., Liu, Y., Xiong, J., Wang, Y., Yang, X., Fu, X., Zheng, L., Luo, G., Xing, M. M. Q., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b06575 · Cited by 14
Tolerogenic Immunomodulation by PEGylated Antigenic Peptides
Pfeil, J. Q., Simonetti, M., Lauer, U., Volkmer, R., von Thülen, B., Durek, P., Krähmer, R., Leenders, F., Hamann, A., & Hoffmann, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.529035 · Cited by 15
“For this approach promising results have recently been reported (21, 23, 66).”
ResultModulating albumin-mediated transport of peptide-drug conjugates for antigen-specific Treg induction
Lau, C. Y. J., Benne, N., Lou, B., Zharkova, O., Ting, H. J., ter Braake, D., van Kronenburg, N. C. H., Fens, M. H. A. M., Broere, F., Hennink, W. E., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.06.025 · Cited by 15
Metadata
- Authors
- Maldonado, R. A., LaMothe, R. A., Ferrari, J. D., Zhang, A.-H., Rossi, R. J., Kolte, P. N., Griset, A. P., O’Neil, C., Altreuter, D. H., Browning, E., Johnston, L., Farokhzad, O. C., Langer, R., Scott, D. W., von Andrian, U. H., & Kishimoto, T. K.
- Affiliations
- Selecta Biosciences (United States) (US)
- Uniformed Services University of the Health Sciences (US)
- Brigham and Women's Hospital (US)
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139;
- Division of Immunology, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115-6017; and
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2014-12-29
- Volume
- 112
- Issue
- 2
- Pages
- E156-65
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC4299193
- OpenAlex
- W2092747941
- Cited by
- 441
- References
- 48
- Citations by year
- 2026: 25 · 2025: 27 · 2024: 31 · 2023: 36 · 2022: 45 · 2021: 42 · 2020: 46 · 2019: 40 · 2018: 50 · 2017: 50 · 2016: 24 · 2015: 23
- FWCI
- 14.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- Funders
- Juvenile Diabetes Research Foundation International (15-2011-265)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- polymeric nanoparticles, rapamycin, biodegradable nanoparticles, TLR agonists, regulatory T cells, B cell tolerance, T cell activation inhibition, experimental autoimmune encephalomyelitis, hemophilia A, factor VIII, hypersensitivity, autoimmune disease, allergy, antidrug antibodies, immunomodulation
- MeSH terms
- Polylactic Acid-Polyglycolic Acid Copolymer, Animals, Antigens, Disease Models, Animal, Encephalomyelitis, Autoimmune, Experimental, Factor VIII, Female, Hemocyanins, Hemophilia A, Humans, Hypersensitivity, Delayed, Immune Tolerance, Immunosuppression Therapy, Immunosuppressive Agents, Mice, Inbred BALB C, Oligodeoxyribonucleotides, Ovalbumin, Peptide Fragments, Peptides, Polyglycolic Acid, Proteins, Recombinant Proteins, CD4-Positive T-Lymphocytes, Lactic Acid, Sirolimus, Mice, Nanoparticles, Nanocapsules, Immunity, Humoral
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.